ArticleJournal of managed care & specialty pharmacy2025

Budget impact analysis of revumenib for the treatment of relapsed or refractory acute leukemias with a

Ivo Abraham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.